Vaxart Stock Forecast, Price & News

-0.14 (-1.76 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume25.36 million shs
Average Volume17.44 million shs
Market Capitalization$953.69 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

Vaxart logo

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.33 out of 5 stars

Medical Sector

830th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

123rd out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vaxart (NASDAQ:VXRT) Frequently Asked Questions

Is Vaxart a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart
or view top-rated stocks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaxart wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Vaxart

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) released its earnings results on Sunday, May, 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company earned $0.50 million during the quarter, compared to analyst estimates of $0.62 million. Vaxart had a negative trailing twelve-month return on equity of 39.81% and a negative net margin of 2,844.24%. The company's revenue was down 82.8% compared to the same quarter last year.
View Vaxart's earnings history

How has Vaxart's stock been impacted by Coronavirus (COVID-19)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT shares have increased by 276.8% and is now trading at $7.80.
View which stocks have been most impacted by COVID-19

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

3 brokers have issued 1 year price objectives for Vaxart's shares. Their forecasts range from $13.00 to $18.00. On average, they expect Vaxart's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 105.1% from the stock's current price.
View analysts' price targets for Vaxart
or view top-rated stocks among Wall Street analysts.

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Ms. Margaret A. Echerd, Sr. VP & Principal Accounting Officer (Age 62, Pay $290.18k)
  • Dr. Sean N. Tucker, Sr. VP & Chief Scientific Officer (Age 53, Pay $353.37k)
  • Mr. Cezar Andrei Floroiu M.B.A., CEO, Pres, Principal Financial Officer & Director (Age 48)
  • Ms. Shaily Jaini Garg, Sr. VP of Clinical Devel. & Project Management
  • Mr. Brant Biehn, Sr. VP of Bus. Operations
  • Dr. Richard M. Schwartz, Sr. VP of Technical Operations
  • Dr. Rajesh Kapoor Ph.D., Sr. VP of Quality
  • Mr. John M. Harland M.B.A., CPA, Consultant (Age 69)

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.59%), Geode Capital Management LLC (1.18%), Principal Financial Group Inc. (0.68%), Principal Financial Group Inc. (0.65%), Citigroup Inc. (0.50%) and Thrivent Financial for Lutherans (0.46%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Margaret Echerd, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart

Which major investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Credit Suisse AG, Barclays PLC, Morgan Stanley, Goldman Sachs Group Inc., Zurcher Kantonalbank Zurich Cantonalbank, Cubist Systematic Strategies LLC, and Pacer Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, Margaret Echerd, and Wouter Latour.
View insider buying and selling activity for Vaxart
or view top insider-selling stocks.

Which major investors are buying Vaxart stock?

VXRT stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., Thrivent Financial for Lutherans, BlackRock Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, Millennium Management LLC, Squarepoint Ops LLC, and JPMorgan Chase & Co.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, and Wouter Latour.
View insider buying and selling activity for Vaxart
or or view top insider-buying stocks.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $7.80.

How much money does Vaxart make?

Vaxart has a market capitalization of $953.69 million and generates $4.05 million in revenue each year. The biotechnology company earns $-32,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Vaxart have?

Vaxart employs 28 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is

Where are Vaxart's headquarters?

Vaxart is headquartered at 290 Utah Ave. Suite 200, South San Francisco CA, 94080.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.